Penn Medicine
Help | Search | Site Map | Contact   

Nicholas Kian Mollanazar, M.D., M.B.A.

faculty photo
Assistant Professor of Clinical Dermatology
Department: Dermatology

Contact information
Hospital of the University of Pennsylvania
Perelman Center for Advanced Medicine
Department of Dermatology
3400 Civic Center Blvd. South
Philadelphia, PA 19104
Education:
BS (Neuroscience and Behavioral Biology)
Emory University, Atlanta, GA, 2010.
MD (Doctor of Medicine)
Temple Univeristy School of Medicine, 2015.
MBA (Master of Business Administration)
Temple University Fox School of Business, Philadelphia, PA, 2015.
Post-Graduate Training
"Preliminary Internal Medicine residency", Pennsylvania Hospital, Philadelphia, PA (completed PGY-1), 2015-2016.
"Dermatology Residency Training", Temple University Hospital, Philadelphia, PA, 2016-2019.
"Chief Dermatology Resident", Temple University School of Medicine, 2016-2017.
Certifications
Board Certified Dermatologist, American Board of Dermatology, 2019.
Certified Epic Physician Builder, Epic Systems, 2020.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have a passion for improving patient access and innovating on our care delivery models. In Dermatology, I have increased the percentage of NPVs seen within 10 days, placing us in the top 10% nationally for academic dermatology centers. I am currently working on piloting asynchronous visits in dermatology and OBGYN. The goal of asynchronous visits is to further improve our access initiatives, by innovating on how and where we deliver care to our patients.

I additionally have worked closely with pharmacy in our department. I noticed many providers were prescribing topicals that are not formulary for our Medicaid patients. Pharmacy was doing prior authorizations for these medications, only to end in a denial and a request to prescribe a covered preferred topical. As such, I met with pharmacy, and we created a universal Medicaid protocol. This protocol allows for interchangeability of commonly prescribed dermatologic medications for our patients so that pharmacy can quickly and efficiently switch to covered alternatives. The end result was a drastic reduction in denied PAs and patients were able to receive treatments in record times. We further expanded the project so that patients were given the option to receive their medication via delivery, if they were unable to come in to pick them up. Furthermore, the program increased revenue for the health system, as the prescriptions tended to stay in house.

Selected Publications

Kwatra SG, Yosipovitch G, Mollanazar NK, Stander S, Kim BS, Hong HC, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB: Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2). CDA Annual Conference Jun 2023.

Yosipovitch G, Mollanazar NK, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade, Staudinger H, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT: Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 29(5): 1180-90, May 2023.

Florez A, Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal , Martincova R: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From Two Phase 3 Trails (LIBERTY-PN PRIME and PRIME 2). Academia Espnola de Dermatologia y Venereologia (AEDV) May 2023.

Kwatra SG, Yosipovitch G, Mollanazar NK, Stander S, Kim BS, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB: Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2). American Academy of Dermatology Annual Meeting Mar 2023.

Sow Y, Wachuku C, Barrera T, Jackson T, Ayoade KO, Taylor SC, Mollanazar NK: Palmer and Plantar Erythema: An Initial Presentation of Undifferentiated Connective Tissue Disease. JAAD Case Reports 35: 94-97, Mar 2023.

Wachuku C, Barrera T, Jackson T, Sow Y, Mollanazar NK, Taylor SC: Upadacitinib, after failure with Dupilumab, as a treatment for chronic pruritus secondary to Polycythemia Vera. JAAD Case Rep 35: 87-89, Mar 2023.

Yosipovitch G, Mollanazar NK, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Wang S, Shi G, Patel K, Bansal A, O'Malley TJ: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trail (LIBERTY-PN PRIME) Hawaii Dermatology Seminar Feb 2023.

Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal A, Martincova R: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trails (LIBERTY-PN PRIME and PRIME2). 4th San Diego Dermatology Symposium Feb 2023.

Yosipovitch G, Kwatra SG, Mollanazar NK, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal E, Martincova R: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From Two Phase 3 Trails (LIBERTY-PN PRIME and PRIME 2). Maui Derm Conference Jan 2023.

Omar D, Brown-Korsah JB, Taylor SC, Mollanzar NK: Automated Pharmacy substitution for medications not covered by medicaid: A model for reducing the burden of prior authorizations in dermatology. J AM Acad Dermatol 88(1): 258-60, Jan 2023.

back to top
Last updated: 07/03/2025
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with a supported browser.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration